A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS ® 500/50 Inhalation Powder/GSK in Healthy Volunteers
Condition: Bioequivalence Interventions: Drug: Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent; Drug: ADVAIR DISKUS® 500/50 Sponsors: Respirent Pharmaceuticals Co Ltd.; BECRO Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2020 Category: Research Source Type: clinical trials